Mersana Therapeutics, a 70-employee Cambridge biotech led by a former top executive at Takeda, said Friday that it plans to raise up to $75 million in an initial public offering.
Mersana revealed in a federal filing that it has applied to list its stock on the Nasdaq under the symbol “MRSN.” The cancer drug developer is led by Anna Protopapas, who previously served as the president of Takeda subsidiary Millennium Pharmaceuticals.
The market for newly public biotechs has appeared to pick up…
Mersana Therapeutics, a 70-employee Cambridge biotech led by a former top executive at Takeda, said Friday that it plans to raise up to $75 million in an initial public offering.
Mersana revealed in a federal filing that it has applied to list its stock on the Nasdaq under the symbol “MRSN.” The cancer drug developer is led by Anna Protopapas, who previously served as the president of Takeda subsidiary Millennium Pharmaceuticals.
The market for newly public biotechs has appeared to pick up…